Skip to main content
SpringerLink
Log in

Hematologic Complications Associated with HSCT

  • Chapter
  • First Online:
Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist

  • 1191 Accesses

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is an increasingly used curative treatment modality, not only for hematologic malignancies but also for a variety of primary immunodeficiencies and nonmalignant hematologic disorders. The expanded use of HSCT is due in large part to improvements in supportive care, T cell depletion approaches, immune suppression, and disease-specific conditioning strategies that have led to improved survival for patients receiving HSCT using alternative donors such as unrelated cord blood, matched or mismatched unrelated adult donors, and partially matched or haploidentical-related donors. While significant hematologic complications associated with well-established approaches for myeloablative matched sibling donor (MSD)-HSCT are relatively uncommon, the increasing use of reduced-intensity conditioning and alternative donor HSCT has been associated with a significant rise in hematologic abnormalities following HSCT. These include autoimmune hemolytic anemia, alloimmune hemolysis due to donor/recipient ABO incompatibility, thrombocytopenia, transplant-associated microangiopathy (TAM), and thromboembolism. Thus, pediatric hematology/oncology specialists who care for pediatric patients who have received HSCT need to be aware of the common presentations and treatment options for hematologic disorders that occur post-HSCT. These HSCT-associated hematologic complications along with their diagnosis and management are discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Petz LD. Immune hemolysis associated with transplantation. Semin Hematol. 2005;42(3):145–55.

    Article  CAS  PubMed  Google Scholar 

  2. Holbro A, Passweg JR. Management of hemolytic anemia following allogeneic stem cell transplantation. Hematol Am Soc Hematol Educ Program. 2015;2015(1):378–84.

    Google Scholar 

  3. Sanz J, Arriaga F, Montesinos P, Orti G, Lorenzo I, Cantero S, et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant. 2007;39(9):555–61.

    Article  CAS  PubMed  Google Scholar 

  4. O'Brien TA, Eastlund T, Peters C, Neglia JP, Defor T, Ramsay NK, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol. 2004;127(1):67–75.

    Article  PubMed  Google Scholar 

  5. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation. 1988;45(3):530–4.

    Article  CAS  PubMed  Google Scholar 

  6. Ahmed I, Teruya J, Murray-Krezan C, Krance R. The incidence of autoimmune hemolytic anemia in pediatric hematopoietic stem cell recipients post-first and post-second hematopoietic stem cell transplant. Pediatr Transplant. 2015;19(4):391–8.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258–71.

    Article  PubMed  Google Scholar 

  8. Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22(3):220–9.

    Article  CAS  PubMed  Google Scholar 

  9. Gupta V, Shukla J, Bhatia BD. Autoimmune hemolytic anemia. Indian J Pediatr. 2008;75(5):451–4.

    Article  CAS  PubMed  Google Scholar 

  10. Barcellini W. Immune Hemolysis: Diagnosis and Treatment Recommendations. Semin Hematol. 2015;52(4):304–12.

    Article  PubMed  Google Scholar 

  11. Chen FE, Owen I, Savage D, Roberts I, Apperley J, Goldman JM, et al. Late onset haemolysis and red cell autoimmunisation after allogeneic bone marrow transplant. Bone Marrow Transplant. 1997;19(5):491–5.

    Article  CAS  PubMed  Google Scholar 

  12. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007;109(6):2643–548.

    Article  CAS  PubMed  Google Scholar 

  13. Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. Blood. 2011;118(6):1693–8.

    Article  CAS  PubMed  Google Scholar 

  14. Horn B, Viele M, Mentzer W, Mogck N, DeSantes K, Cowan M. Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant. 1999;24(9):1009–13.

    Article  CAS  PubMed  Google Scholar 

  15. Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem cell transplantation. Bone Marrow Transplant. 2002;29(4):365–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sanz J, Arango M, Carpio N, Montesinos P, Moscardo F, Martin G, et al. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. Bone Marrow Transplant. 2014;49(8):1084–8.

    Article  CAS  PubMed  Google Scholar 

  17. Wen L, Roberts SJ, Viney JL, Wong FS, Mallick C, Findly RC, et al. Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in alpha beta(+) T cells. Nature. 1994;369(6482):654–8.

    Article  CAS  PubMed  Google Scholar 

  18. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304–13.

    Article  CAS  PubMed  Google Scholar 

  20. O'Connell N, Goodyer M, Gleeson M, Storey L, Williams M, Cotter M, et al. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation. Pediatr Transplant. 2014;18(1):E22–4.

    Article  PubMed  Google Scholar 

  21. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930–6.

    Article  CAS  PubMed  Google Scholar 

  22. Park JA, Lee HH, Kwon HS, Baik CR, Song SA, Lee JN. Sirolimus for refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review of the treatment of post-transplant autoimmune hemolytic anemia. Transfus Med Rev. 2016;30(1):6–14.

    Article  PubMed  Google Scholar 

  23. Uz B, Ozdemir E, Aksu S, Akyol TK, Jones R. Successful treatment of autoimmune hemolytic anemia with steroid, IVIg, and plasmapheresis in a haploidentical transplant recipient. Turk J Haematol. 2012;29(2):199–200.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Arbach O, Funck R, Seibt F, Salama A. Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. Transfus Med Hemother. 2012;39(3):221–3.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100(2):704–6.

    Article  CAS  PubMed  Google Scholar 

  26. Hosoba S, Jaye DL, Cohen C, Roback JD, Waller EK. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2015;55(2):259–64.

    Article  CAS  PubMed  Google Scholar 

  27. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114(4):891–8.

    Article  CAS  PubMed  Google Scholar 

  28. Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia. 2007;21(3):511–4.

    Article  CAS  PubMed  Google Scholar 

  29. Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831–8.

    Article  CAS  PubMed  Google Scholar 

  30. Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transfus Med Rev. 2010;24(3):195–210.

    Article  PubMed  Google Scholar 

  31. Jaime-Perez JC, Rodriguez-Martinez M, Gomez-de-Leon A, Tarin-Arzaga L, Gomez-Almaguer D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp (Warsz). 2013;61(5):385–95.

    Article  CAS  Google Scholar 

  32. Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1152–8.

    Article  CAS  PubMed  Google Scholar 

  33. Rowley SD, Donato ML, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46(9):1167–85.

    Article  CAS  PubMed  Google Scholar 

  34. Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M, et al. Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant. 2010;16(9):1315–23.

    Article  PubMed  Google Scholar 

  35. Kim JG, Sohn SK, Kim DH, Baek JH, Lee KB, Min WS, et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;35(5):489–95.

    Article  CAS  PubMed  Google Scholar 

  36. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86(7):2842–8.

    CAS  PubMed  Google Scholar 

  37. Curley C, Pillai E, Mudie K, Western R, Hutchins C, Durrant S, et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange. Transfusion. 2012;52(2):291–7.

    Article  CAS  PubMed  Google Scholar 

  38. Griffith LM, McCoy JP Jr, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128(5):668–75.

    Article  CAS  PubMed  Google Scholar 

  39. Daniel-Johnson J, Schwartz J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation? Transfusion. 2011;51(6):1143–9.

    Article  PubMed  Google Scholar 

  40. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol. 2001;112(3):787–95.

    Article  CAS  PubMed  Google Scholar 

  41. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood. 1997;90(12):4665–78.

    CAS  PubMed  Google Scholar 

  42. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. 2004;33(4):419–23.

    Article  CAS  PubMed  Google Scholar 

  43. Zaja F, Geromin A, Patriarca F, Puglisi S, Cerno M, Sperotto A, et al. Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. Am J Hematol. 2011;86(9):790–2.

    Article  PubMed  Google Scholar 

  44. Reid R, Bennett JM, Becker M, Chen Y, Milner L, Phillips GL 2nd, et al. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol. 2012;87(7):743–5.

    Article  CAS  PubMed  Google Scholar 

  45. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–60.

    Article  PubMed  Google Scholar 

  46. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1519–38.

    Article  CAS  PubMed  Google Scholar 

  47. Li G, Liu F, Mao X, Hu L. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation. Transfus Apher Sci. 2011;45(1):21–4.

    Article  PubMed  Google Scholar 

  48. Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion. 1999;39(6):586–92.

    Article  CAS  PubMed  Google Scholar 

  49. Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant. 2000;26(8):925–7.

    Article  CAS  PubMed  Google Scholar 

  50. Laundy GJ, Bradley BA, Rees BM, Younie M, Hows JM. Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion. 2004;44(6):814–25.

    Article  CAS  PubMed  Google Scholar 

  51. Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion. 1990;30(7):622–5.

    Article  CAS  PubMed  Google Scholar 

  52. Murphy MF, Metcalfe P, Thomas H, Eve J, Ord J, Lister TA, et al. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization. Br J Haematol. 1986;62(3):529–34.

    Article  CAS  PubMed  Google Scholar 

  53. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood. 1988;71(5):1402–7.

    CAS  PubMed  Google Scholar 

  54. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation—a prospective analysis. Transfusion. 1998;38(9):839–47.

    Article  CAS  PubMed  Google Scholar 

  55. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Neame PB, Kelton JG, Walker IR, Stewart IO, Nossel HL, Hirsh J. Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood. 1980;56(1):88–92.

    CAS  PubMed  Google Scholar 

  57. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103(2):114–20.

    Article  CAS  PubMed  Google Scholar 

  58. Heffner JE. Platelet-neutrophil interactions in sepsis--platelet guilt by association? Intensive Care Med. 1997;23(4):366–8.

    Article  CAS  PubMed  Google Scholar 

  59. Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1988;71(2):383–7.

    CAS  PubMed  Google Scholar 

  60. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang. 1994;66(3):200–5.

    Article  CAS  PubMed  Google Scholar 

  61. Rio B, Andreu G, Nicod A, Arrago JP, Dutrillaux F, Samama M, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood. 1986;67(6):1773–6.

    CAS  PubMed  Google Scholar 

  62. Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P, et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2012;26(4):746–56.

    Article  CAS  PubMed  Google Scholar 

  63. Pulanic D, Lozier JN, Pavletic SZ. Thrombocytopenia and hemostatic disorders in chronic graft versus host disease. Bone Marrow Transplant. 2009;44(7):393–403.

    Article  CAS  PubMed  Google Scholar 

  64. Liem LM, Fibbe WE, van Houwelingen HC, Goulmy E. Serum transforming growth factor-beta1 levels in bone marrow transplant recipients correlate with blood cell counts and chronic graft-versus-host disease. Transplantation. 1999;67(1):59–65.

    Article  CAS  PubMed  Google Scholar 

  65. Hirayama Y, Sakamaki S, Tsuji Y, Sagawa T, Chiba H, Matsunaga T, et al. Thrombopoietin concentrations in peripheral blood correlated with platelet numbers in two patients with thrombocytopenia by chronic graft-versus-host disease. Am J Hematol. 2003;73(4):285–9.

    Article  PubMed  Google Scholar 

  66. Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, et al. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;35(3):299–301.

    Article  CAS  PubMed  Google Scholar 

  67. Price S, Cumpston A, Altaha R. Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant. Hematology. 2006;11(1):43–4.

    Article  PubMed  Google Scholar 

  68. Narvios A, Reddy V, Martinez F, Lichtiger B. Slow infusion of platelets: a possible alternative in the management of refractory thrombocytopenic patients. Am J Hematol. 2005;79(1):80.

    Article  PubMed  Google Scholar 

  69. Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis. 2005;16(4):287–90.

    Article  PubMed  Google Scholar 

  70. Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127(8):989–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(8):571–5.

    Article  PubMed  Google Scholar 

  72. Rosenthal J, Pawlowska A, Bolotin E, Cervantes C, Maroongroge S, Thomas SH, et al. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus. Pediatr Blood Cancer. 2011;57(1):142–6.

    Article  PubMed  Google Scholar 

  73. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122(12):2003–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Laskin BL, Maisel J, Goebel J, Yin HJ, Luo G, Khoury JC, et al. Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transplantation. 2013;96(2):217–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3):831–46.

    Article  CAS  PubMed  Google Scholar 

  76. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011;118(6):1452–62.

    Article  CAS  PubMed  Google Scholar 

  77. Laskin B, Goebel J, Davies S, Khoury J, Bleesing J, Mehta P, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;46(5):682–9.

    Article  CAS  PubMed  Google Scholar 

  78. Shulman H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med. 1981;305(23):1392–5.

    Article  CAS  PubMed  Google Scholar 

  79. Atkinson K, Biggs JC, Hayes J, Ralston M, Dodds AJ, Concannon AJ, et al. Cyclosporin A associated nephrotoxicity in the first 100 days after allogeneic bone marrow transplantation: three distinct syndromes. Br J Haematol. 1983;54(1):59–67.

    Article  CAS  PubMed  Google Scholar 

  80. Bonser RS, Adu D, Franklin I, McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet. 1984;2(8415):1337.

    Article  CAS  PubMed  Google Scholar 

  81. Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):328–36.

    Article  CAS  PubMed  Google Scholar 

  82. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102(5):1601–5.

    Article  CAS  PubMed  Google Scholar 

  83. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29(3):191–204.

    Article  PubMed  Google Scholar 

  84. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.

    Article  PubMed  Google Scholar 

  85. Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bambach B, et al. Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation. 2004;78(10):1515–22.

    Article  PubMed  Google Scholar 

  86. Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2002;118(4):1112–9.

    Article  PubMed  Google Scholar 

  87. George JN, Li X, McMinn JR, Terrell DR, Vesely SK, Selby GB. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004;44(2):294–304.

    Article  PubMed  Google Scholar 

  88. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008;23(10):1761–7.

    Article  PubMed  Google Scholar 

  89. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant. 1994;14(4):495–504.

    CAS  PubMed  Google Scholar 

  90. Schriber JR, Herzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol. 1997;34(2):126–33.

    CAS  PubMed  Google Scholar 

  91. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102–11.

    Article  CAS  PubMed  Google Scholar 

  92. Nabhan C, Kwaan HC. Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura. Hematol Oncol Clin North Am. 2003;17(1):177–99.

    Article  PubMed  Google Scholar 

  93. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111(4):1122–9.

    Article  CAS  PubMed  Google Scholar 

  94. Corti P, Uderzo C, Tagliabue A, Della Volpe A, Annaloro C, Tagliaferri E, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2002;29(6):542–3.

    Article  CAS  PubMed  Google Scholar 

  95. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518–25.

    Article  CAS  PubMed  Google Scholar 

  96. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81.

    Article  CAS  PubMed  Google Scholar 

  97. Hillmen P, Muus P, Roth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013;161(2):279–80.

    Article  PubMed  Google Scholar 

  99. Chaturvedi S, Neff A, Nagler A, Savani U, Mohty M, Savani BN. Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2016;51(4):473–8.

    Article  CAS  PubMed  Google Scholar 

  100. Brandao LR, Kletzel M, Boulad F, Kurtzberg J, Maloney K, Fligman I, et al. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer. 2008;50(6):1240–6.

    Article  PubMed  Google Scholar 

  101. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, Bandini G, et al. Endothelium and bone marrow transplantation. Bone Marrow Transplant. 1996;17(2):277–80.

    CAS  PubMed  Google Scholar 

  102. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood. 2008;112(3):504–10.

    Article  CAS  PubMed  Google Scholar 

  103. Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E, et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation. 2002;74(9):1303–9.

    Article  PubMed  Google Scholar 

  104. Labrador J, Gonzalez-Rivero J, Monroy R, Lozano FS, Lopez-Corral L, Caballero MD, et al. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center. Thromb Res. 2016;142:52–6.

    Article  CAS  PubMed  Google Scholar 

  105. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.

    Article  CAS  PubMed  Google Scholar 

  106. Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention—an unresolved issue. Haematologica. 2008;93(8):1227–32.

    Article  PubMed  Google Scholar 

  107. Patel NY, Chilsen AM, Mathiason MA, Kallies KJ, Bottner WA. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg. 2012;204(6):1014–9. discussion 9–20

    Article  PubMed  Google Scholar 

  108. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    Mala K. Talekar MD & Timothy Olson MD, PhD

  2. Oncology Clinical Development, GlaxoSmithKline, Collegeville, PA, USA

    Mala K. Talekar MD

Authors
  1. Mala K. Talekar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy Olson MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mala K. Talekar MD .

Editor information

Editors and Affiliations

  1. Division of Pediatric Oncology/Hematology, Penn State Health Children’s Hospital and Penn State Cancer Institute at the Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

    Valerie I. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Talekar, M.K., Olson, T. (2018). Hematologic Complications Associated with HSCT. In: Brown, V. (eds) Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist. Springer, Cham. https://doi.org/10.1007/978-3-319-63146-2_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63146-2_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63144-8

  • Online ISBN: 978-3-319-63146-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation